Cell-based therapy for chronic ischemic heart disease--a clinical perspective
Emerson C Perin1, Guilherme V Silva
1Stem Cell Center, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX, USA. eperin@bluegate.com
Insights
Cardiovascular stem cell therapy using adult bone marrow cells is safe and feasible for chronic ischemic heart disease, showing modest functional improvements. Further phase 2 and 3 trials are needed to confirm these findings.
Area of Science:
- Regenerative Medicine
- Cardiovascular Research
- Stem Cell Therapy
Background:
- Ischemic heart disease (IHD) affects millions globally, causing significant myocardial damage.
- Current treatments for IHD aim to restore blood flow and improve heart function.
- Cell therapy offers a promising regenerative approach for damaged heart muscle.
Purpose of the Study:
- To review major clinical studies on cardiovascular stem cell therapy in patients with chronic ischemic heart disease.
- To evaluate the safety, feasibility, and efficacy of current cell-based therapies for myocardial ischemia.
- To identify the most frequently used cell types and explore potential mechanisms of action.
Main Methods:
- Systematic review of clinical studies on cardiovascular stem cell therapy for chronic ischemic heart disease.
- Inclusion of all relevant studies due to the early stage of clinical investigation.
- Analysis of data on safety, functional status, quality of life, and underlying mechanisms.
Main Results:
- Adult cell-based therapy for chronic myocardial ischemia is safe and feasible.
- Initial trials with autologous bone marrow mononuclear cells show modest functional improvements.
- Potential benefits may involve multiple mechanisms, including paracrine effects.
Conclusions:
- Cardiovascular stem cell therapy is a safe and feasible option for patients with chronic ischemic heart disease.
- Early results suggest modest functional gains, warranting further investigation.
- Future phase 2 and 3 trials are essential to validate these findings and optimize therapeutic strategies.
Abstract:
In patients with ischemic heart disease, the goal of cell therapy is to improve perfusion and function of the damaged heart muscle. For this review, we selected articles that reported the findings from the major clinical studies of cardiovascular stem cell therapy in patients with chronic ischemic heart disease. Because of the current status of development of clinical investigation in this field, all relevant studies were included. Initial clinical trials have shown that adult cell-based therapy is safe and may improve the quality of life and the functional status of patients with chronic myocardial ischemia. Adult bone marrow mononuclear cells have been most frequently used in cardiac cell therapy trials to date, but new cell types are now being assessed in both preclinical and clinical studies. Although not well defined, mechanisms underlying the benefits associated with cell therapy are most likely multiple and include a paracrine effect. Cell therapy in patients with chronic ischemic heart disease has been shown to be safe and feasible. Initial data have shown that cell therapy with autologous bone marrow cells is associated with modest functional improvements. This finding needs to be confirmed in subsequent phase 2 and 3 trials.
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Coronary Artery Disease II: Pathophysiology
01:29Heart Failure II: Pathophysiology
01:29Cardiomyopathy V: Interprofessional Care
01:26Atherosclerosis III: Management